FY2025 Earnings Estimate for AVDL Issued By Leerink Partnrs

Avadel Pharmaceuticals plc (NASDAQ:AVDL - Free Report) - Stock analysts at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for shares of Avadel Pharmaceuticals in a research note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of $0.95 for the year, down from their prior estimate of $1.05. The consensus estimate for Avadel Pharmaceuticals' current full-year earnings is ($0.50) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals' FY2026 earnings at $2.00 EPS and FY2028 earnings at $3.15 EPS.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.03. The business had revenue of $50.00 million for the quarter, compared to analysts' expectations of $48.43 million. Avadel Pharmaceuticals had a negative return on equity of 92.12% and a negative net margin of 52.53%. The firm's quarterly revenue was up 624.6% compared to the same quarter last year. During the same quarter last year, the business earned ($0.41) earnings per share.

Several other research firms have also weighed in on AVDL. HC Wainwright reduced their target price on Avadel Pharmaceuticals from $27.00 to $25.00 and set a "buy" rating on the stock in a report on Wednesday. Needham & Company LLC reiterated a "buy" rating and set a $22.00 price objective on shares of Avadel Pharmaceuticals in a report on Tuesday. Finally, Oppenheimer boosted their price objective on Avadel Pharmaceuticals from $29.00 to $30.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Avadel Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $24.43.

Avadel Pharmaceuticals Trading Down 3.6 %

Shares of AVDL stock traded down $0.43 on Thursday, reaching $11.59. The company had a trading volume of 2,349,258 shares, compared to its average volume of 1,187,195. The company has a 50-day moving average of $13.62 and a 200-day moving average of $15.09. Avadel Pharmaceuticals has a 12 month low of $10.39 and a 12 month high of $19.09. The stock has a market cap of $1.12 billion, a PE ratio of -14.67 and a beta of 1.47.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in AVDL. Janus Henderson Group PLC boosted its stake in shares of Avadel Pharmaceuticals by 16.1% during the 1st quarter. Janus Henderson Group PLC now owns 12,915,160 shares of the company's stock worth $218,182,000 after buying an additional 1,789,830 shares during the last quarter. Gendell Jeffrey L boosted its position in Avadel Pharmaceuticals by 1.7% during the first quarter. Gendell Jeffrey L now owns 5,708,118 shares of the company's stock valued at $96,410,000 after purchasing an additional 92,768 shares during the last quarter. Braidwell LP grew its stake in Avadel Pharmaceuticals by 16.9% in the third quarter. Braidwell LP now owns 3,388,939 shares of the company's stock valued at $44,446,000 after purchasing an additional 490,300 shares in the last quarter. Brandes Investment Partners LP grew its stake in Avadel Pharmaceuticals by 1.5% in the second quarter. Brandes Investment Partners LP now owns 1,483,439 shares of the company's stock valued at $20,894,000 after purchasing an additional 21,214 shares in the last quarter. Finally, Kennedy Capital Management LLC increased its position in shares of Avadel Pharmaceuticals by 1.1% during the 1st quarter. Kennedy Capital Management LLC now owns 653,147 shares of the company's stock worth $11,032,000 after purchasing an additional 7,273 shares during the last quarter. Institutional investors own 69.19% of the company's stock.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.